What Does Immunitas Therapeutics Do?

Total employees34
HeadquartersCambridge
Founded2019

Immunitas Therapeutics is a clinical-stage biotechnology company committed to discovering and developing novel, differentiated antibody-based therapeutics for cancer. Their core strategy involves reprogramming the tumor microenvironment (TME) by precisely targeting innate immune cells and specific cancer cell vulnerabilities. Leveraging a sophisticated single-cell genomics platform, Immunitas identifies and validates novel immune targets to forge impactful treatments for patients battling difficult-to-treat cancers. Their lead investigational candidate, IMT-009, an anti-CD161 antibody, is currently advancing through clinical trials for various malignancies.

Where Is Immunitas Therapeutics's Headquarters?

HQ Function

The Cambridge headquarters serves as the primary center for Immunitas Therapeutics' research and development, clinical operations, corporate strategy, and administrative functions.

Notable Features:

Located within a modern life sciences building, the headquarters likely features state-of-the-art laboratory spaces for drug discovery and translational research, alongside collaborative office environments. Its Cambridge location offers unparalleled access to a dense network of academic institutions, research hospitals, and fellow biotech companies.

Work Culture:

As a dynamic, clinical-stage biotechnology firm, the work culture at Immunitas Therapeutics is likely characterized by a strong emphasis on scientific innovation, collaboration, agility, and a patient-centric mission. Employees are driven by the pursuit of breakthroughs in cancer treatment within a rigorous and intellectually stimulating environment.

HQ Significance:

The Cambridge headquarters is strategically significant, placing Immunitas at the heart of the biotech ecosystem. This allows for enhanced collaboration, talent acquisition, and access to cutting-edge technologies and research, all vital for advancing their therapeutic pipeline.

Values Reflected in HQ: The choice of a premier Cambridge location and investment in advanced facilities underscores Immunitas's commitment to scientific excellence, innovation, fostering top-tier talent, and being at the forefront of developing transformative cancer therapies.

Location:

While Immunitas Therapeutics is headquartered in the United States, its clinical development activities, particularly for its lead programs, may involve collaborations with clinical trial sites and research institutions internationally to access diverse patient populations and expertise. The company's scientific collaborations and partnerships could also extend globally as it seeks to advance its innovative cancer therapies.

Street Address:

300 Third Street

City:

Cambridge

State/Province:

MA

Country:

USA

Where Else Does Immunitas Therapeutics Operate Around the World?

No additional office locations available.

Buying Intent Signals for Immunitas Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Immunitas Therapeutics? Meet the Executive Team

As of April 2025, Immunitas Therapeutics' leadership includes:

Jeffrey Goldberg - Chief Executive Officer
Amanda Wagner, PhD - Chief Business Officer
Tomer Nissim Nir, PhD - Chief Scientific Officer
Sath Shukla, MD, MS - Chief Medical Officer
Lea Bou-Abdallah, PhD - SVP, Head of CMC

Who's Investing in Immunitas Therapeutics?

Immunitas Therapeutics has been backed by several prominent investors over the years, including:

Longitude Capital
Agent Capital
Medical Excellence Capital (MEC)
Leaps by Bayer
Novartis Venture Fund
Atlas Venture
Alexandria Venture Investments
Evotec
Sanofi Ventures
Takeda Ventures (via Baxalta Ventures)
Longwood Fund

What Leadership Changes Has Immunitas Therapeutics Seen Recently?

Hire1
Exits0

In the past 12 months (relative to May 2024), Immunitas Therapeutics has focused on strengthening its scientific leadership. The company appointed a new Chief Scientific Officer to drive its research and discovery pipeline. No major executive departures have been publicly announced during this period.

New Appointments:

Tomer Nissim Nir, PhD, Dr. Tomer Nissim Nir was appointed as Chief Scientific Officer, bringing significant expertise in immunology and oncology to lead Immunitas's research and discovery efforts.

What Technology (Tech Stack) Is Used byImmunitas Therapeutics?

Discover the tools Immunitas Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Immunitas Therapeutics Email Formats and Examples

While Immunitas Therapeutics does not publicly confirm its exact email format, a common structure utilized by many companies in the life sciences and biotechnology sector is [first_initial][last_name]@[companydomain.com]. Variations may exist.

[first_initial][last]@immunitastx.com

Format

jgoldberg@immunitastx.com

Example

70%

Success rate

What's the Latest News About Immunitas Therapeutics?

PR NewswireDecember 5, 2023

Immunitas Therapeutics Presents Promising Preclinical Data on Lead Program IMT-009 at the 65th ASH Annual Meeting

Immunitas Therapeutics shared compelling preclinical findings for IMT-009, its CD161 inhibitor, at the American Society of Hematology (ASH) Annual Meeting. The data underscored its potential as both a monotherapy and in combination treatments for hematologic malignancies....more

PR NewswireJune 7, 2023

Immunitas Therapeutics Appoints Tomer Nissim Nir, Ph.D., as Chief Scientific Officer

Immunitas Therapeutics announced the appointment of Tomer Nissim Nir, Ph.D., as its new Chief Scientific Officer. Dr. Nir brings extensive experience in immunology and oncology drug discovery to spearhead the company's research initiatives....more

PR NewswireApril 11, 2023

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of Lead Candidate IMT-009 for Solid Tumors and Hematologic Malignancies

Immunitas Therapeutics reported the dosing of the first patient in its Phase 1/2 clinical study evaluating IMT-009, a novel monoclonal antibody targeting CD161. The trial includes patients with advanced solid tumors and hematologic malignancies....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Immunitas Therapeutics, are just a search away.